Search Results

The Kinetix Group and Pfizer Inflammation and Immunology received a PM360 Pharma Choice Award for their recent health equity initiative.

Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading Health Canada licensed psychedelics pharmaceutical manufacturer, specializing in controlled substances such as botanical psilocybin and MDMA, has entered a Letter of Intent (LOI) with ATMA Journey Centers (ATMA). ATMA is a pioneering Canadian firm focused on advancing innovative solutions in psychedelic-assisted therapy.

Seegene Inc. (KQ096530), a leading South Korean company providing a total solution for PCR molecular diagnostics, announced its selection of Microsoft as a technology partner for its SG OneSystemTM business in London, UK, on January 23 to realize ‘a world free from all diseases.’

BD, a leading global medical technology company, and Edwards Lifesciences, announced a definitive agreement under which BD will acquire Edwards’ Critical Care product group, a global leader in advanced monitoring solutions, for $4.2 billion in cash, unlocking new value creation opportunities and enhancing BD’s portfolio of smart connected care solutions.

Centene Corporation announced today it has completed the previously announced divestiture of Circle Health Group, one of the U.K.'s largest independent operators of hospitals, to Pure Health, the largest integrated healthcare network in the Middle East.

LSL PHARMA GROUP INC., a Canadian integrated pharmaceutical company, is pleased to announce the completion of the acquisition of Virage Santé, a company specializing in the manufacturing and marketing of natural health products, based in Lévis, Quebec.

Syneos Health®, a leading fully integrated biopharmaceutical solutions organization, announced a strategic multi-year agreement with Microsoft.

Heartbeat Health, the nation’s largest decentralized cardiology provider, and Karoo Health, the only operational provider of cardiac value-based care enablement with published value-based results, announced the formation of a unique value-based enterprise, creating the first national, scalable, end-to-end cardiac value-based care solution for payers, at-risk entities, and provider networks.